Corey Davis
Stock Analyst
(n/a)
# 4,425
Out of 4,433 analysts
18
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Downgrades: Neutral | n/a | $1.80 | - | 3 | Jun 11, 2018 | |
| SCYX SCYNEXIS | Assumes: Buy | n/a | $2.41 | - | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $27.88 | +43.47% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | n/a | $5.75 | - | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | n/a | $5.58 | - | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | n/a | $31.51 | - | 3 | Jan 19, 2018 | |
| CARA Cara Therapeutics | Initiates: Buy | n/a | $0.81 | - | 1 | Jan 19, 2018 | |
| AGRX Agile Therapeutics | Assumes: Buy | n/a | $0.40 | - | 2 | Oct 2, 2017 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | n/a | $110.49 | - | 1 | Aug 25, 2017 |
Nektar Therapeutics
Jun 11, 2018
Downgrades: Neutral
Price Target: n/a
Current: $1.80
Upside: -
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: n/a
Current: $2.41
Upside: -
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $27.88
Upside: +43.47%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: n/a
Current: $5.75
Upside: -
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: n/a
Current: $5.58
Upside: -
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: n/a
Current: $31.51
Upside: -
Cara Therapeutics
Jan 19, 2018
Initiates: Buy
Price Target: n/a
Current: $0.81
Upside: -
Agile Therapeutics
Oct 2, 2017
Assumes: Buy
Price Target: n/a
Current: $0.40
Upside: -
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: n/a
Current: $110.49
Upside: -